Advancing regenerative medicine through Taiwan-Japan collaboration: StellaCell.Bio and Cell Source join forces to expand clinical applications of exosomes

• Enhancing Taiwan-Japan medical collaboration to accelerate clinical applications of exosomes

Taiwan Healthcare One Venture Capital Limited Partnership (hereinafter referred to as "Taiwan Healthcare One") announced today that, together with its portfolio company StellarCell BioMedicine Inc. (hereinafter referred to as "StellarCell.Bio")—represented by General Manager Guo, Yi Ru—and strategic partner Spirit Scientific Co. Ltd. (hereinafter referred to as "Spirit Scientific"), represented by its Chairman Lin, Dao Long, they successfully met with Tokyo Stock Exchange-listed company CellSource Co., Ltd. (hereinafter referred to as "CellSource") in Tokyo, Japan. This meeting marks a significant step forward in Taiwan-Japan collaborations within the biotechnology sector. Both parties reached a consensus to jointly promote the clinical application of exosomes and collaborate with Japanese medical institutions, aiming to accelerate the integration and broader adoption of exosome technologies.
StellarCell.Bio strengthens proprietary exosome technology and takes a leading position in entering clinical trials in Japan
As a leading company in Japan's regenerative medicine sector, CellSource has long been dedicated to the development of cell therapy and regenerative medicine technologies, accumulating extensive clinical experience and a large patient base. Therefore, the successful introduction of StellarCell Bio’s high-concentration, high-stability exosome products is expected to further enhance CellSource’s technological strengths and expand its market reach, providing advanced and more efficient regenerative medicine solutions to a broader market.
Guo, Yi Ru, General Manager of StellarCell.Bio, stated, "We are very honored to establish a solid partnership with CellSource, Japan’s top biotech company, through the introduction facilitated by Taiwan Healthcare One. This strategic partnership will not only accelerate StellarCell.Bio’s long-term development in the exosome technology field, but also expedite our product’s entry into the Japanese market, directly serving more people in need. Through this partnership, we look forward to gaining valuable insights from the Japanese market to further optimize our product formulations, enhance technology applications, and even develop more innovative technologies to meet diverse clinical needs."
Preliminary plans and market expansion: Strengthening ties with Japan and fostering large-scale clinical frameworks
According to the latest market research, the global regenerative medicine market is projected to grow at an annual rate of over 15% in the next five years, potentially surpassing US$150 billion by 2030. This Taiwan-Japan collaboration can potentially drive breakthroughs in regenerative medicine. Both parties plan to progressively expand exosome clinical frameworks and co-host the second Starnic Preventive Medicine Industry Forum, fostering exchange between industry and clinical regenerative medicine as well as providing more comprehensive technologies and applications for global health.